This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEB59082_M.jpg
Growing investor interest in the bio-pharmaceuticals industry, combined with various technology innovations leading to breakthrough drug trials, have allowed BCRX to generate $19.10 million in revenues in the first quarter, ended March 31. This growth trajectory is expected to continue. Analysts expect the company’s top line to improve 478.5% in the current quarter (ending June 2021), and 3216.7% in the current year.
However, the company’s profitability is expected to remain low; the Street expects its EPS to remain negative until at least 2022.
